Small Molecule CDMO Market Size, Share & Trends Analysis Report By Drug Type (Generics, Innovators), By Product (APIs, Finished Drug Products), By Application (Oncology, CVD, CNS Conditions), By Region, And Segment Forecasts, 2024 - 2030
Small Molecule CDMO Market Growth & Trends
The global small molecule CDMO market size is expected to reach USD 108.46 billion by 2030, registering a CAGR of 7.1% from 2024 to 2030, according to a new study by Grand View Research, Inc. Exploration of innovative technologies in small molecule drug development, expansion of pharmaceutical pipelines with a focus on small molecule therapeutics, growing reliance on contract development and manufacturing organizations (CDMOs) for cost-effective and specialized manufacturing services, regulatory frameworks supporting efficient drug development & manufacturing processes, and CDMOs expanding manufacturing capacities to meet industry demands are few of the factors supporting market growth. For pharmaceutical companies, innovation and easy access to clinics are critical factors.
Small-scale companies and specialty pharmaceutical players increasingly rely on delivering these important requirements within the industry. Many CDMOs establish themselves as one-stop-shop companies. The one-stop-shop service model is where a CDMO offers everything, from active pharmaceutical ingredient (API) to dosage form and early development to commercialization. To provide these services, a CDMO must have a wide range of enabling technologies and specialized handling capabilities that help address specific problem statements. A significant number of CDMOs across the globe providing all research, development, and manufacturing services is expected to support market growth. The high prevalence of chronic ailments is another considerable factor supporting the development of novel small molecule-based therapeutics, thus boosting CDMO services demand.
The International Diabetes Federation (IDF) states that the incidence of diabetes is rising gradually in the country. It states that in 2022, over 140 million people in China had diabetes, and 174.4 million are expected to be diagnosed by 2030. High consumption of unhealthy fats and a sedentary lifestyle are major factors contributing to the high incidence of diabetes. The growing burden of diabetes is expected to drive CDMO services demand in the country. Substantial investment in pharmaceutical R&D is a significant driver bolstering industry growth. As pharmaceutical companies intensify their efforts in discovering & developing small molecule therapeutics, there is a corresponding rise in demand for CDMO services. These services are crucial in the efficient & cost-effective development & manufacturing of small-molecule drugs.
Small Molecule CDMO Market Report Highlights
- The API segment accounted for the largest share of 62.3% in 2023 due to increased R&D initiatives for novel medicine development. The robust drug pipelines of major pharmaceutical players also propel segment growth
- The generics drug type segment is anticipated to have the highest CAGR of 8.0% from 2024 to 2030. The high burden of diseases, such as cancer, diabetes, and cardiovascular disorders (CVDs), and initiatives by the governments to improve access to generic drugs are the key factors contributing to segment growth
- The oncology segment held the highest revenue share of 35.1% in 2023 owing to an increasing number of cancer cases globally. Furthermore, increased government reimbursement policies and a rise in financing for developing small molecule oncology therapies are expected to boost segment growth
- Asia Pacific is anticipated to witness the highest CAGR of 7.7% from 2024 to 2030. Due to significantly cheaper manufacturing costs than North America & Europe and favorable laws, Asia Pacific, particularly China & India, has remained the dominant regional market
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Product
- 1.1.2. Drug Type
- 1.1.3. Application
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR’s internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.3.5.1. Data for primary interviews in North America
- 1.3.5.2. Data for primary interviews in Europe
- 1.3.5.3. Data for primary interviews in Asia Pacific
- 1.3.5.4. Data for primary interviews in Latin America
- 1.3.5.5. Data for Primary interviews in MEA
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.2. Parent Market Analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Drug Type outlook
- 2.2.3. Application outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Small Molecule CDMO Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rise in drug development pipelines
- 3.2.1.2. Growing reliance on CDMOS for cost-effective and specialized manufacturing services.
- 3.2.1.3. Capacity expansions by CDMOS
- 3.2.1.4. Technological advancements
- 3.2.2. Market restraint analysis
- 3.2.2.1. Growing demand for biologics
- 3.2.2.2. Complexity and challenges in synthesis of certain small molecules, impacting manufacturing efficiency
- 3.3. Small Molecule CDMO Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- Chapter 4. Small Molecule CDMO Market: Product Estimates & Trend Analysis
- 4.1. Definitions and Scope
- 4.1.1. Active Pharmaceutical Ingredients (API)
- 4.1.2. Finished Drug Products
- 4.2. Product Market Share, 2023 & 2030
- 4.3. Segment Dashboard
- 4.4. Global Small Molecule CDMO Market by Product Outlook
- 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5.1. Active Pharmaceutical Ingredients (APIs)
- 4.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 4.5.2. Finished Drug Products
- 4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
- Chapter 5. Small Molecule CDMO Market: Drug Type Estimates & Trend Analysis
- 5.1. Definitions and Scope
- 5.1.1. Innovators
- 5.1.2. Generics
- 5.2. Drug Type Market Share, 2023 & 2030
- 5.3. Segment Dashboard
- 5.4. Global Small Molecule CDMO Market by Drug Type Outlook
- 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5.1. Innovators
- 5.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 5.5.2. Generics
- 5.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
- Chapter 6. Small Molecule CDMO Market: Application Estimates & Trend Analysis
- 6.1. Definitions and Scope
- 6.1.1. Oncology
- 6.1.2. Cardiovascular Disease
- 6.1.3. Central Nervous System (CNS) Conditions
- 6.1.4. Autoimmune/Inflammation
- 6.1.5. Others
- 6.2. Application Market Share, 2023 & 2030
- 6.3. Segment Dashboard
- 6.4. Global Small Molecule CDMO Market by Application Outlook
- 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.5.1. Oncology
- 6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.2. Cardiovascular Disease
- 6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.3. Central Nervous System (CNS) Conditions
- 6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.4. Autoimmune/Inflammation
- 6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.5. Others
- 6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
- Chapter 7. Small Molecule CDMO Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2023 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Global Regional Market Snapshot
- 7.4. North America
- 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
- 7.5. Europe
- 7.5.1. UK
- 7.5.1.1. Key Country Dynamics
- 7.5.1.2. Competitive Scenario
- 7.5.1.3. Regulatory Framework
- 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
- 7.5.2. Germany
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
- 7.5.3. France
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
- 7.5.4. Italy
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
- 7.5.5. Spain
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competitive Scenario
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
- 7.5.6. Denmark
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Competitive Scenario
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
- 7.5.7. Sweden
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competitive Scenario
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
- 7.5.8. Norway
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Competitive Scenario
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
- 7.6. Asia Pacific
- 7.6.1. Japan
- 7.6.1.1. Key Country Dynamics
- 7.6.1.2. Competitive Scenario
- 7.6.1.3. Regulatory Framework
- 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
- 7.6.2. India
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
- 7.6.4. South Korea
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Competitive Scenario
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Competitive Scenario
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
- 7.6.6. Thailand
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Competitive Scenario
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
- 7.7. Latin America
- 7.7.1. Brazil
- 7.7.1.1. Key Country Dynamics
- 7.7.1.2. Competitive Scenario
- 7.7.1.3. Regulatory Framework
- 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
- 7.7.2. Mexico
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
- 7.8. MEA
- 7.8.1. South Africa
- 7.8.1.1. Key Country Dynamics
- 7.8.1.2. Competitive Scenario
- 7.8.1.3. Regulatory Framework
- 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
- 7.8.2. Saudi Arabia
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Competitive Scenario
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
- 7.8.3. UAE
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Competitive Scenario
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
- 7.8.4. Kuwait
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Competitive Scenario
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030
- Chapter 8. Competitive Landscape
- 8.1. Market Participant Categorization
- 8.1.1. Innovators
- 8.1.2. Market Leaders
- 8.1.3. Emerging Players
- 8.1.4. Company Market Share Analysis, 2023
- 8.2. Company Profiles
- 8.2.1. Lonza
- 8.2.1.1. Company overview
- 8.2.1.2. Financial performance
- 8.2.1.3. Service benchmarking
- 8.2.1.4. Strategic initiatives
- 8.2.2. Catalent, Inc
- 8.2.2.1. Company overview
- 8.2.2.2. Financial performance
- 8.2.2.3. Service benchmarking
- 8.2.2.4. Strategic initiatives
- 8.2.3. Thermo Fisher Scientific Inc.
- 8.2.3.1. Company overview
- 8.2.3.2. Financial performance
- 8.2.3.3. Service benchmarking
- 8.2.3.4. Strategic initiatives
- 8.2.4. Cambrex Corporation
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Service benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. Bellen Chemistry
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Service benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. Siegfried Holding AG
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Service benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. Recipharm AB
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Service benchmarking
- 8.2.7.4. Strategic initiatives
- 8.2.8. Eurofins Scientific
- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Service benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. Aurigene Pharmaceutical Services Ltd.
- 8.2.9.1. Company overview
- 8.2.9.2. Financial performance
- 8.2.9.3. Service benchmarking
- 8.2.9.4. Strategic initiatives
- 8.2.10. CordenPharma International
- 8.2.10.1. Company overview
- 8.2.10.2. Financial performance
- 8.2.10.3. Service benchmarking
- 8.2.10.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook